Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David T Melnekoff

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
Advances in Experimental Medicine and Biology|March 1, 2022
Single-Cell Sequencing Technologies in Precision OncologyDavid T Melnekoff, Alessandro Laganà
JCO Precision Oncology|June 15, 2022
A Three-Gene Signature Predicts Response to Selinexor in Multiple MyelomaPaula Restrepo, Sherry Bhalla, Yogita Ghodke-Puranik, et al.
Science Advances|November 17, 2021
Patient similarity network of newly diagnosed multiple myeloma identifies patient subgroups with distinct genetic features and clinical implicationsSherry Bhalla, David T Melnekoff, Adolfo Aleman, et al.
Blood Advances|August 26, 2022
Sequencing T-cell redirection therapies leads to deep and durable responses in patients with relapsed/refractory myelomaTarek H Mouhieddine, Oliver Van Oekelen, David T Melnekoff, et al.
Blood Cancer Discovery|September 16, 2024
Multiple Myeloma Risk and Outcomes Are Associated with Pathogenic Germline Variants in DNA Repair GenesSantiago Thibaud, Ryan L Subaran, Scott Newman, et al.
Blood|November 3, 2022
Interventions and outcomes of patients with multiple myeloma receiving salvage therapy after BCMA-directed CAR T therapyOliver Van Oekelen, Karthik Nath, Tarek H Mouhieddine, et al.
Blood Neoplasia|June 24, 2025
Predictors of response to venetoclax and therapeutic potential of CDK7 inhibition in multiple myelomaRudra P Dutta, Santiago Thibaud, Violetta Leshchenko, et al.
Leukemia & Lymphoma|August 20, 2020
A phase II study of pomalidomide, daily oral cyclophosphamide, and dexamethasone in relapsed/refractory multiple myelomaOliver Van Oekelen, Samir Parekh, Hearn J Cho, et al.
The Journal of Clinical Investigation|February 20, 2024
Immunotherapy-resistant acute lymphoblastic leukemia cells exhibit reduced CD19 and CD22 expression and BTK pathway dependencySarah Aminov, Orsi Giricz, David T Melnekoff, et al.
Blood Advances|November 5, 2025
Long-term Remission After Cilta-Cel in Multiple Myeloma Is Linked to Diverse T Cells and Low Myeloid SuppressionJunia Vieira Dos Santos, David T Melnekoff, Adolfo Aleman, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Advances in Experimental Medicine and Biology|March 1, 2022
Single-Cell Sequencing Technologies in Precision OncologyDavid T Melnekoff, Alessandro Laganà
JCO Precision Oncology|June 15, 2022
A Three-Gene Signature Predicts Response to Selinexor in Multiple MyelomaPaula Restrepo, Sherry Bhalla, Yogita Ghodke-Puranik, et al.
Science Advances|November 17, 2021
Patient similarity network of newly diagnosed multiple myeloma identifies patient subgroups with distinct genetic features and clinical implicationsSherry Bhalla, David T Melnekoff, Adolfo Aleman, et al.
Blood Advances|August 26, 2022
Sequencing T-cell redirection therapies leads to deep and durable responses in patients with relapsed/refractory myelomaTarek H Mouhieddine, Oliver Van Oekelen, David T Melnekoff, et al.
Blood Cancer Discovery|September 16, 2024
Multiple Myeloma Risk and Outcomes Are Associated with Pathogenic Germline Variants in DNA Repair GenesSantiago Thibaud, Ryan L Subaran, Scott Newman, et al.
Blood|November 3, 2022
Interventions and outcomes of patients with multiple myeloma receiving salvage therapy after BCMA-directed CAR T therapyOliver Van Oekelen, Karthik Nath, Tarek H Mouhieddine, et al.
Blood Neoplasia|June 24, 2025
Predictors of response to venetoclax and therapeutic potential of CDK7 inhibition in multiple myelomaRudra P Dutta, Santiago Thibaud, Violetta Leshchenko, et al.
Leukemia & Lymphoma|August 20, 2020
A phase II study of pomalidomide, daily oral cyclophosphamide, and dexamethasone in relapsed/refractory multiple myelomaOliver Van Oekelen, Samir Parekh, Hearn J Cho, et al.
The Journal of Clinical Investigation|February 20, 2024
Immunotherapy-resistant acute lymphoblastic leukemia cells exhibit reduced CD19 and CD22 expression and BTK pathway dependencySarah Aminov, Orsi Giricz, David T Melnekoff, et al.
Blood Advances|November 5, 2025
Long-term Remission After Cilta-Cel in Multiple Myeloma Is Linked to Diverse T Cells and Low Myeloid SuppressionJunia Vieira Dos Santos, David T Melnekoff, Adolfo Aleman, et al.
Pageof 2